The risk of relapse after Anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 111, Issue 5, 2016, Pages 632-647

  Gisbert, Javier P ^a   Marín, Alicia C ^a   Chaparro, María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; CERTOLIZUMAB PEGOL; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

BIOLOGICAL THERAPY; CROHN DISEASE; DRUG WITHDRAWAL; HUMAN; ILEITIS; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; RETREATMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; INFLAMMATORY BOWEL DISEASES; RECURRENT DISEASE; TREATMENT WITHDRAWAL;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; CERTOLIZUMAB PEGOL; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84966658369     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.54     Document Type: Review

References (68)

1. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29
2. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn?s disease. Inflamm Bowel Dis 2009; 15: 1295-301
3. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients wiThearly-stage Crohn?s disease. Gastroenterology 2010; 138: 463-8. quiz e10-1
4. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fi stulizing Crohn?s disease. Gastroenterology 2005; 128: 862-9
5. Clarke K, Regueiro M. Stopping immunomodulators and biologics in Inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012; 18: 174-9
6. Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn?s disease: when should we stop? Curr Drug Targets 2010; 11: 148-51
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700
8. Review Manager (RevMan) [Computer program]. Version 5.2. The Nordic Cochrane Centre, TCC: Copenhagen, Denmark, 2013
9. Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-term Crohn?s disease recurrence. Clin Gastroenterol Hepatol 2014; 12: 1494-502
10. Calafiore ACC, Rizzello F, Gionchetti P, et al. The long-term clinical course of refractory chronic pouchitis after infliximab therapy. Dig Liver Dis 2013; 45S: S143-S144. abstract P.08.2
11. Viazis N, Giakoumis M, Koukouratos T, et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis 2013; 7: e457-e460
12. Ardizzone S, Colombo E, Maconi G, et al. Infliximab in treatment of Crohn?s disease: the Milan experience. Dig Liver Dis 2002; 34: 411-8
13. Brooks AJ, Roninson K, Wright A, et al. Infliximab induction therapy alone for ulcerative colitis does not result in long term remission. Gut 2012; 61: A166-A167
14. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the Efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6
15. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn?s disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
16. De Bie CI, Hummel TZ, Kindermann A, et al. The duration of Effect of infliximab maintenance treatment in paediatric Crohn?s disease is limited. Aliment Pharmacol Ther 2011; 33: 243-50
17. Echarri AOV, Rodriguez JA, Gallego JC, et al. Predictors of relapse after discontinuing anti-TNF therapy in Crohn?s disease patients on deep remission. J Crohns Colitis 2013; 7: S171
18. Papamichael K, Vande Casteele N, Gils A, et al. Long-Term outcome of patients with Crohn?s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2015; 13: 1103-10
19. Rismo R, Olsen T, Cui G, et al. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn?s disease. Scand J Gastroenterol 2013; 48: 311-9
20. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn?s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010; 105: 1574-82
21. Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn?s disease. J Crohns Colitis 2012; 6: 160-73
22. Bortlik M, Ďuricova D, Lukaš M, et al. Infliximab trough levels at treatment discontinuation are associated with increased risk of disease relapse in patients with Inflammatory bowel diseases. 20th United European Gastroenterology Week 2012: P0870
23. Brooks AJ, Sebastian S, Cross SS, et al. Outcome of elective withdrawal of anti-tumour necrosis factor-alpha therapy in patients with Crohn?s disease in established remission. J Crohns Colitis 2015; pii: jjv000 [e-pub ahead of print
24. Guidi L, Ratto C, Semeraro S, et al. Combined therapy with infliximab and seton drainage for perianal fi stulizing Crohn?s disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008; 12: 111-7
25. Domenech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn?s disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005; 22: 1107-13
26. Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr 2008; 46: 293-8
27. Dart RJ, Griffin N, Taylor K, et al. Reassessment of Crohn?s disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? Frontline Gastroenterol 2014; 5: 176-82
28. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn?s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70 e5; quiz e31
29. Lu C, Waugh A, Bailey RJ, et al. Crohn?s disease genotypes of patients in remission vs. relapses after infliximab discontinuation. World J Gastroenterol 2012; 18: 5058-64
30. Molnar T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn?s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-33
31. Molander P, Farkkila M, Salminen K, et al. Outcome after discontinuation of TNF alpha-blocking therapy in patients with Inflammatory bowel disease in deep remission. Inflamm Bowel Dis 2014; 20: 1021-8
32. Echarri A, Ollero V, Gallego C, et al. Anti-TNF withdrawal in IBD patients on deep remission. Risk factors of relapse. 20th United European Gastroenterology Week 2012: P0287
33. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in Inflammatory bowel disease: Efficacy and safety long-term followup. World J Gastroenterol 2007; 13: 5238-44
34. Ciria V, Silva P, Leo E, et al. Factors infl uencing recurrence following suspension of biological treatment. Importance of mucosal healing. J Crohns Colitis 2014; 8: P487
35. Chauvin A, Le Thuaut A, Belhassan M, et al. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn?s disease: a retrospective study. Dig Liver Dis 2014; 46: 695-700
36. Ramos L, Hernandez A, Carrillo M, et al. Outcome of treatment with biological agents in Crohn?s disease: 117 patients in 5 years from a tertiary referral center. J Crohns Colitis 2014; 8: P398
37. Luppino I, Spagnuolo R, Marasco R, et al. Withdrawal of infliximab (IFX) after achieving remission: outcome in a cohort of Inflammatory bowel disease (IBD) patients. Dig Liver Dis 2013; 45S: S100-S101
38. Marino M, Zucchi E, Fabbro M, et al. Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: single centre preliminary data. J Crohns Colitis 2014; 8: P401
39. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn?s disease: a population-based study. Inflamm Bowel Dis 2011; 17: 2144-52
40. Annunziata ML, Papparella LG, Sansoni I, et al. Normalized wall thickness at MRE predicts clinical remission in Crohn?s disease after infliximab discontinuation: a 5 years follow-up. J Crohns Colitis 2014; 8: P402
41. Steenholdt C, Molazahi A, Ainsworth MA, et al. Outcome after discontinuation of infliximab in patients with Inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518-27
42. Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn?s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32: 1129-34
43. Nuti F, Conte F, Cavallari N, et al. Long term Efficacy of infliximab in Inflammatory bowel disease at a single tertiary center. Dig Liver Dis 2010; 42: S326-S327
44. Farkas K, Lakatos PL, Nagy F, et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013; 48: 1394-8
45. Armuzzi A, Marzo M, Felice C, et al. Long-term scheduled therapy with infliximab in Inflammatory bowel disease: a single-centre observational study. Gastroenterology 2010; 238: S-691
46. Munoz C, Bravo MT, Ortiz de Zarate J, et al. Mucosal healing in patients with ulcerative colitis treated with infliximab. What happens after treatment is discontinued? J Crohns Colitis 2014; 8: P405
47. Dai C, Liu WX, Jiang M, et al. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One 2014; 9: e110797
48. Domenech E, Manosa M, Navarro M, et al. Long-term methotrexate for Crohn?s disease: safety and Efficacy in clinical practice. J Clin Gastroenterol 2008; 42: 395-9
49. Felice C, Pugliese D, Guidi L, et al. Retreatment with infliximab in Inflammatory bowel disease: tolerability and Effectiveness of diff erent re-induction regimens. J Crohns Colitis 2014; 8: P363
50. Quinn MA, Conaghan PG, O?Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35
51. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four diff erent treatment strategies in patients wiThearly rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90
52. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18: 460-4
53. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010; 69: 1286-91
54. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in Inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 40: 338-53
55. Molnar T, Farkas K, Miheller P, et al. Is the Efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in diff erent behavior types of Crohn?s disease? J Crohns Colitis 2008; 2: 322-6
56. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the Effects of infliximab on perianal fi stulizing Crohn?s disease. Am J Gastroenterol 2003; 98: 332-9
57. Armuzzi A, Van Assche G, Reinisch W, et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in Inflammatory bowel disease. J Crohns Colitis 2012; 6: 492-502
58. D?Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn?s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212 quiz 213
59. Pittet V, Froehlich F, Maillard MH, et al. When do we dare to stop biological or immunomodulatory therapy for Crohn?s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis 2013; 7: 820-6
60. Farkas K, Lakatos PL, Szucs M, et al. Frequency and prognostic role of mucosal healing in patients with Crohn?s disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol 2014; 20: 2995-3001
61. Casanova MJ, Chaparro M, Garcia-Sanchez V, et al. Evolution after anti-TNF Drug discontinuation in patients with Inflammatory bowel disease (IBD): a multicenter long-term follow-up study. Gastroenterology 2015; 148: S-476
62. Gisbert JP, Marin AC, Chaparro M. Systematic review: factors associated with relapse of Inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther 2015; 42: 391-405
63. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn?s disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24
64. Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn?s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 2013; 19: 1622-30
65. Domenech E, Zabana Y, Manosa M, et al. Infliximab reintroduction is not associated to a higher rate of immune-related adverse Effects in patients with Inflammatory bowel disease initially treated with a three-infusion induction regimen. J Clin Gastroenterol 2010; 44: 34-7
66. Sorrentino D, Nash P, Viladomiu M, et al. Stopping anti-TNF agents in patients with Crohn?s disease in remission: is it a feasible long-term strategy? Inflamm Bowel Dis 2014; 20: 757-66
67. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009; 76: 350-5
68. Baraliakos X, Listing J, Rudwaleit M, et al. Safety and Efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007; 34: 510-5